AUSTIN, Texas, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today announced that its management will provide a corporate update at the forthcoming Evercore ISI HealthCONx BioPharma, MedTools, and Devices Conference, and the BMO Capital Markets Prescriptions for Success Healthcare Conference.
Evercore ISI HealthCONx – BioPharma, MedTools, & Devices Conference
Date: Wednesday, November 28
Time: 7:35 am Eastern Time
Location: Boston Harbor Hotel
Webcast: http://wsw.com/webcast/evercore2/mtem/
BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
Date: Wednesday, December 12
Time: 9:00 am Eastern Time
Location: The Mandarin Oriental, New York
About Molecular Templates
Molecular Templates is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases. For additional information, please visit Molecular Templates’ website at www.mtem.com.
Investor Contact:
Adam Cutler
Chief Financial Officer
adam.cutler@mtem.com
862-204-4006
Source: Molecular Templates, Inc.